These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 22509763)

  • 1. Multivalent peptidomimetic conjugates: a versatile platform for modulating androgen receptor activity.
    Levine PM; Imberg K; Garabedian MJ; Kirshenbaum K
    J Am Chem Soc; 2012 Apr; 134(16):6912-5. PubMed ID: 22509763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen receptor antagonism by divalent ethisterone conjugates in castrate-resistant prostate cancer cells.
    Levine PM; Lee E; Greenfield A; Bonneau R; Logan SK; Garabedian MJ; Kirshenbaum K
    ACS Chem Biol; 2012 Oct; 7(10):1693-701. PubMed ID: 22871957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computationally identified novel diphenyl- and phenylpyridine androgen receptor antagonist structures.
    Söderholm AA; Viiliäinen J; Lehtovuori PT; Eskelinen H; Roell D; Baniahmad A; Nyrönen TH
    J Chem Inf Model; 2008 Sep; 48(9):1882-90. PubMed ID: 18712859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system.
    Culig Z; Hoffmann J; Erdel M; Eder IE; Hobisch A; Hittmair A; Bartsch G; Utermann G; Schneider MR; Parczyk K; Klocker H
    Br J Cancer; 1999 Sep; 81(2):242-51. PubMed ID: 10496349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells.
    Wang Y; Dehigaspitiya DC; Levine PM; Profit AA; Haugbro M; Imberg-Kazdan K; Logan SK; Kirshenbaum K; Garabedian MJ
    Cancer Res; 2016 Sep; 76(17):5124-32. PubMed ID: 27488525
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of non-LBD inhibitor for androgen receptor by structure-guide design.
    Ryu BJ; Kim N; Kim JT; Koo TS; Yoo SE; Jeong SH; Kim SH; Kang NS
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3887-90. PubMed ID: 23727044
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Niphatenones, glycerol ethers from the sponge Niphates digitalis block androgen receptor transcriptional activity in prostate cancer cells: structure elucidation, synthesis, and biological activity.
    Meimetis LG; Williams DE; Mawji NR; Banuelos CA; Lal AA; Park JJ; Tien AH; Fernandez JG; de Voogd NJ; Sadar MD; Andersen RJ
    J Med Chem; 2012 Jan; 55(1):503-14. PubMed ID: 22148427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 20-Aminosteroids as a novel class of selective and complete androgen receptor antagonists and inhibitors of prostate cancer cell growth.
    Fousteris MA; Schubert U; Roell D; Roediger J; Bailis N; Nikolaropoulos SS; Baniahmad A; Giannis A
    Bioorg Med Chem; 2010 Oct; 18(19):6960-9. PubMed ID: 20826091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Theranostic Pt(IV) Conjugate with Target Selectivity for Androgen Receptor.
    Qin X; Fang L; Zhao J; Gou S
    Inorg Chem; 2018 May; 57(9):5019-5029. PubMed ID: 29667815
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of oxobenzimidazoles and oxindoles as novel androgen receptor antagonists.
    Guo C; Pairish M; Linton A; Kephart S; Ornelas M; Nagata A; Burke B; Dong L; Engebretsen J; Fanjul AN
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2572-8. PubMed ID: 22377517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel steroidal antiandrogen targeting wild type and mutant androgen receptors.
    Andrieu T; Bertolini R; Nichols SE; Setoud R; Frey FJ; Baker ME; Frey BM
    Biochem Pharmacol; 2011 Dec; 82(11):1651-62. PubMed ID: 21907706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological properties of androgen receptor pure antagonist for treatment of castration-resistant prostate cancer: optimization from lead compound to CH5137291.
    Kawata H; Arai S; Nakagawa T; Ishikura N; Nishimoto A; Yoshino H; Shiraishi T; Tachibana K; Nakamura R; Sato H
    Prostate; 2011 Sep; 71(12):1344-56. PubMed ID: 21308717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
    Mashima T; Okabe S; Seimiya H
    Mol Pharmacol; 2010 Nov; 78(5):846-54. PubMed ID: 20709811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zyflamend inhibits the expression and function of androgen receptor and acts synergistically with bicalutimide to inhibit prostate cancer cell growth.
    Yan J; Xie B; Capodice JL; Katz AE
    Prostate; 2012 Feb; 72(3):244-52. PubMed ID: 21656835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
    Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
    J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer.
    Jackson KM; Frazier MC; Harris WB
    Anticancer Res; 2007; 27(3B):1483-8. PubMed ID: 17595765
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of Protein Degradation Inducers of Androgen Receptor by Conjugation of Androgen Receptor Ligands and Inhibitor of Apoptosis Protein Ligands.
    Shibata N; Nagai K; Morita Y; Ujikawa O; Ohoka N; Hattori T; Koyama R; Sano O; Imaeda Y; Nara H; Cho N; Naito M
    J Med Chem; 2018 Jan; 61(2):543-575. PubMed ID: 28594553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and synthesis of 4-benzyl-1-(2H)-phthalazinone derivatives as novel androgen receptor antagonists.
    Inoue K; Urushibara K; Kanai M; Yura K; Fujii S; Ishigami-Yuasa M; Hashimoto Y; Mori S; Kawachi E; Matsumura M; Hirano T; Kagechika H; Tanatani A
    Eur J Med Chem; 2015 Sep; 102():310-9. PubMed ID: 26295173
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line.
    Lazier CB; Thomas LN; Douglas RC; Vessey JP; Rittmaster RS
    Prostate; 2004 Feb; 58(2):130-44. PubMed ID: 14716738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-activity relationship of novel (benzoylaminophenoxy)phenol derivatives as anti-prostate cancer agents.
    Kazui Y; Fujii S; Yamada A; Ishigami-Yuasa M; Kagechika H; Tanatani A
    Bioorg Med Chem; 2018 Oct; 26(18):5118-5127. PubMed ID: 30228001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.